Narbiekova A. V., Voronkova Y. S., Pavlova O. O., Budkova H. V., Simonova O. M., Merzliakova N. V., Voronkova O. S.

DYNAMICS OF BIOCHEMICAL MARKERS IN BLOOD IN CORONAVIRUS DISEASE

---

Show/Download

About the author:

Narbiekova A. V., Voronkova Y. S., Pavlova O. O., Budkova H. V., Simonova O. M., Merzliakova N. V., Voronkova O. S.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

The pandemic caused by coronavirus disease (COVID-19) is currently one of the most serious and influential problems in modern medicine. It has presented the medical community with a number of important challenges, including studying the dynamics of the disease and developing new approaches to diagnosis and treatment. Bio chemical markers have proven to be one of the most convenient tools in such studies, as tracking their dynam ics allows for rapid assessment of the patient's condition, prediction of changes, and adjustment of therapeutic strategies to achieve optimal results. The aim of this study was to analyze the dynamics of biochemical markers in the blood of patients with COVID-19 and to establish possible links between their changes and the severity of the disease. Hemostasis system indicators (D-dimer, fibrinogen, activated partial thromboplastin time), as well as C-reactive protein (CRP), procalcitonin, and ferritin were studied. The results showed that CRP levels varied across all age groups regardless of gender, with significantly higher values observed in elderly patients: men – 88.94±9.13, women – 76.49±7.51. In younger patients, CRP levels were lower: men – 41.63±8.95, women – 39.70±5.43, indicat ing a more pronounced inflammatory response in older age groups. Procalcitonin levels exceeded the norm by 6-7 times. Coagulogram indicators showed an upward trend: D-dimer concentration in elderly and senile patients was as follows: men: 1.750±0.500, women: 1.940±0.300 for the elderly; men: 1.890±0.240, women: 1.910±1.200 for the senile age group, which is almost three times higher than the values in younger groups and indicates an increased risk of thrombosis. Fibrinogen levels were elevated (7.60±0.80 g/L) and accompanied by a slowdown in prothrombin, thrombin, and activated partial thromboplastin times, as well as a significant increase in D-dimer. These changes indicate the activation of hypercoagulable syndrome, which contributes to the formation of blood clots. Studying the characteristics of SARS-CoV-2 in patients with chronic diseases requires taking into account the significant variability of these indicators, therefore, their analysis should be individual and take into account the clinical picture of each patient. This approach allows for a more accurate assessment of the dynamics of the disease and the development of personalized treatment strategies

Tags:

Bibliography:

1. Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Ann Transl Med. 2020;8:497. DOI: 10.21037/atm.2020.03.157.
2. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020;21(5):343-360. DOI: 10.1631/jzus.b2000083.
3. Sarhan AR, Hussein TA, Flaih MH, Hussein KR. A biochemical analysis of patients with COVID-19 infection. Biochem Res Int. 2021;2021:1383830. DOI: 10.1155/2021/1383830.
4. Eriten B, Eriten S. Reporting of biochemical blood values in COVID-19 patients: a retrospective study. Medicine (Baltimore). 2023;102(44):e35833. DOI: 10.1097/md.0000000000035833.
5. Niraula A, Baral N, Lamsal M, Bataju M, Thapa S. Potential role of biochemical markers in the prognosis of COVID-19 patients. SAGE Open Med. 2022;10:20503121221108613. DOI: 10.1177/20503121221108613.
6. Zaidan NK, Mohammed WM, Rashid IM. Comparative analysis of biochemical and hematological parameters in COVID-19 patients. J Nat Sci Biol Med. 2024;15:28-35. DOI: 10.4103/jnsbm.JNSBM_15_1_3.
7. Mandal PK, Vidhatri R. Changes in hematological and other laboratory parameters in COVID-19 infection. J Hematol Allied Sci. 2021;1:99 106. DOI: 10.25259/JHAS_5_2022.
8. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568-576. DOI: 10.1002/jmv.25748.
9. Ministerstvo okhorony zdorov’ya Ukrayiny. Protokol vedennya patsiyentiv z COVID-19 «Zhyva» klinichna nastanova. Kyyiv: MOZ Ukrayiny; 2023. 162 s. Dostupno: https://www.dec.gov.ua/wp-content/uploads/2023/05/2023_kn _covid-19.pdf. [in Ukrainian].
10. Melnyk O. COVID-19 ta suputni zakhvoriuvannia. Laboratorna sprava. 2020;8(17):10-20. [in Ukrainian].
11. Pertseva TO, Bielosludtseva KO, Kirieieva TV, Konopkina LI, Krykhtina MA, Basina BA, et al. Nehospitalna pnevmoniia na tli koronavirusnoi khvoroby (COVID-19): pryntsypy diahnostyky ta vyznachennia faktoriv ryzyku obtiazhennia patolohichnoho protsesu. Medychni perspektyvy. 2020;3:50-61 DOI: 10.26641/2307-0404.2020.3.214807. [in Ukrainian].
12. Gupta N, Ish P, Kumar R, Dev N, Yadav SR, Malhotra N, et al. Evaluation of the clinical profile, laboratory parameters and outcome of two hundred COVID-19 patients from a tertiary centre in India. Licensee PAGEPress. 2020;90:1507. DOI: 10.4081/monaldi.2020.1507.
13. Matysek A, Studnicka A, Smith WM, Hutny M, Gajewski P, Filipiak KJ, et al. Influence of co-morbidities during SARS-CoV-2 infection in an Indian population. Front Med (Lausanne). 2022;9:962101. DOI: 10.3389/fmed. 2022.962101.
14. Akmakji AJ, Albarzanji ZNM, Alsulaiman ANF. Biochemical and immunological insights into COVID-19 multisystem involvement in Iraqi patients. Regul Mech Biosyst. 2025;16(1):e25025. Available from: https://medicine.dp.ua/index.php/med/article/view/1185.
15. Voronkova OS, Pavlova OO, Starishko OM, Prykhodko OM, Narbiekova AV, Simonova OM. Changes in hematological indicators in patients with coronavirus disease. Bull Probl Biol Med. 2023;1(168):120-130. DOI: 10.29254/2077-4214-2023-1-168-120-130.
16. Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G, et al. Antibody tests for identification of current and past infection with SARS CoV-2. Cochrane Database Syst Rev. 2022;11(11):CD013652. DOI: 10.1002/14651858. cd013652.pub2.
17. Chauhan N, Soni S, Jain U. Optimizing testing regimes for the detection of COVID-19 in children and older adults. Expert Rev Mol Diagn. 2021;21(10):999-1016. DOI: 10.1080/14737159.2021.1962708.
18. Zhang N, Xie T, Ning W, He R, Zhu B, Mao Y. The severity of COVID-19 and its determinants: a systematic review and meta-analysis in China. Sustainability. 2021;13:5305. DOI: 10.3390/su13095305.
19. Uzunova G, Pallanti S, Hollander E. Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection and in the post-COVID-19 recovery phase. Int J Psychiatry Clin Pract. 2021;25(2):115-131. DOI: 10.1080/13651501.2021.1887264.
20. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2. MMWR Morb Mortal Wkly Rep. 2020;69(14):411. DOI: 10.15585/mmwr.mm6914e1.
21. Pokrovska NK, Krekhtiuk VA, Skliarova OIe, Mahiiovych SR, Skliarov YeIa. Diahnostychna tsinnist vyznachennia deiakykh markeriv zapalennia pry koronavirusnii infektsii zalezhno vid kharakteru urazhennia lehenevoi tkanyny. Visnyk medychnykh i biolohichnykh doslidzhen. 2022;2(12):35-38. [in Ukrainian].
22. Dolatkazina Ye. Otsinka parametriv krovi ta COVID-2019. Materialy V Mizhnarodnoyi studentskoyi naukovo-tekhnichnoyi konferentsiyi Pryrodni ta humanitarni nauky. Aktualni pytannya; 2022 Kvit 28-29; Ternopil. Ternopil: Ternopilskyy natsionalnyy tekhnichnyy universytet im.I.Pulyuya; 2022. s. 107-108. Dostupno: https://m.tntu.edu.ua/storage/pages/00000893/Zbirnyk 2022.pdf. [in Ukrainian].
23. Khyts A. COVID-19: vcheni vyznachyly novi biomarkery prohresuiuchoho perebihu zakhvoriuvannia. Ukrainskyi medychnyi chasopys. 2021;5:1-3. [in Ukrainian].
24. Antipova SV, Shepil OV, Lukianova NYu, Chekhun VF. Zviazok rivnia ferrytynu u syrovattsi krovi ta pukhlynnii tkanyni z chutlyvistiu do neoadiuvantnoi khimioterapii u khvorykh na rak molochnoi zalozy. Onkolohiia. 2013;15(3):204-209. [in Ukrainian].
25. Shostakovych-Koretskaya L, Kireyeva T, Shevchenko-Makarenko O, Turchin M, Chumak V, Chortok V, et al. Kliniko-laboratorni markery perebihu SARS-CoV-2 COVID-19 u hospitalizovanykh khvorykh. Medychni perspektyvy. 2021;4:48-55 DOI: 10.26641/2307 0404.2021.4.248085. [in Ukrainian]
26. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775-1776. DOI: 10.1001/jama.2020.4683.
27. Haiova LV, Ivanytska YuA. Zminy biokhimichnykh pokaznykiv krovi pid vplyvom COVID-19 u patsiientiv z netypovoiu vidpoviddiu. Naukovi zapysky. Biolohichni nauky. 2025;1:43-51. [in Ukrainian].
28. Kasnakova P, Kilova K. Recovery and rehabilitation of patients with COVID-19 and post-COVID-19 syndrome. Med J. 2021;53(3):346-347.
29. Sirchak YeS, Sabovchyk KV, Reho OYu, Arkhiy EI. Zminy koahuliatsiinoi systemy krovi u khvorykh na nealkoholnu zhyrovu khvorobu pechinky ta urazhennia nyrok pry infikuvanni COVID-19. Problemy klinichnoi pediatrii. 2022;1:72-78. DOI: 10.24144/1998-6475.2022.55.7278. [in Ukrainian].

Publication of the article:

«Bulletin of problems biology and medicine», 2026 Issue 1, 180, 298-309 pages, index UDC 616.98:578.834]-074:577.1

DOI:

10.29254/2077-4214-2026-1-180-298-309